close

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company also discovers small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its clinical development programs include lorcaserin in Phase 3 trial program for the treatment of obesity; APD791, an anti-thrombotic drug candidate, which has completed Phase 1a and Phase 1b clinical trials; and APD125 that is in Phase 2b clinical trial for the treatment of insomnia. The company's clinical development programs also include APD597, an oral GPR119 agonist that is in Phase 1 clinical trial for the treatment of type 2 diabetes; APD916 drug candidate, which has completed preclinical development for the treatment of narcolepsy and cataplexy; and APD811, a preclinical drug candidate for the treatment of pulmonary arterial hypertension. Its drug candidates use GPCR-focused drug discovery and development approach, as well as technologies, including constitutively activated receptor technology and melanophore technology. The company has collaborations with Merck & Co., Inc. to develop therapeutics for atherosclerosis and related disorders; and Ortho-McNeil-Janssen Pharmaceuticals, Inc. to further develop compounds for the potential treatment of type 2 diabetes and other disorders. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.79
Volume	(mio) 2.28
Volume Avg	(mio) 4.19
52 Week High	2.62
52 Week Low	1.21
PE	N/A
PE (group average)	39
EPS Year	-0.88
EPS change Q/Q	-52.17%
EPS change Q/Q Yr ago	-6.06%
EPS change Q/Q next Q est	-150%
EPS change Y/Y	-29.06%
REV change Q/Q	-2.5%
REV change Q/Q Yr ago	56%
EPS next Q est	-0.14
EPS next Y est	-0.40
Divident Annual	0.00
Dividend Yield	0%